Zhitong Finance App News, Shu Taishen (300204.SZ) issued an announcement. Recently, the company obtained a summary report on the phase iB clinical study of STSP-0902 injection for the treatment of oligospermia. Among participants in the health trial, the safety and tolerability of STSP-0902 injection was good for multiple subcutaneous injections and a single subcutaneous injection within the dosage range of the protocol design, and an upward trend in semen parameters can be observed after multiple doses. Among participants in the health trial, STSP-0902 injection was not ADA positive for multiple times and a single subcutaneous injection within the dosage range of the protocol design, and the immunogenicity was low. The test results support STSP-0902 injection for further clinical research.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.